Results 191 to 200 of about 1,267,326 (360)
Objective The objective of this study was to estimate the minimal important change (MIC) and minimal clinically important difference (MCID) for pain and physical function in individuals with hip osteoarthritis (OA) following a physiotherapist‐guided exercise intervention.
Yareni Guerrero +8 more
wiley +1 more source
Changes in pharmaceutical industry payments to physicians after New Jersey's 2018 restriction. [PDF]
Patel NG, Ramachandran R, Ross JS.
europepmc +1 more source
High Healthcare Utilization Preceding Diagnosis with Juvenile Idiopathic Arthritis
Objective Though early diagnosis improves long‐term outcomes, Juvenile Idiopathic Arthritis (JIA) patients often experience prolonged, circuitous paths to diagnosis. To inform diagnostic improvement, we sought to characterize healthcare utilization in the year preceding diagnosis.
Anna Costello +5 more
wiley +1 more source
Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure. [PDF]
Chin KK +16 more
europepmc +1 more source
Do women newly diagnosed with breast cancer and consulting surgeon assess decision-making equally?
Inger Schou +3 more
openalex +1 more source
Objective To support high‐quality, patient‐centered care for systemic lupus erythematosus (SLE), the American College of Rheumatology (ACR) developed evidence‐based measures incorporating clinical and patient‐reported outcomes measures (PROMs). Using the Consolidated Framework for Implementation Research (CFIR), we conducted semi‐structured interviews ...
Catherine Nasrallah +13 more
wiley +1 more source
Determinants of consulting a physician for mental distress in Japan: Analyses of the general population with a particular focus on the moderate distress group. [PDF]
Hanaoka S +5 more
europepmc +1 more source
People with systemic autoimmune and rheumatic diseases (SARDs) are at higher risk than the general population of experiencing adverse pregnancy and perinatal outcomes such as preeclampsia, intrauterine growth restriction, and maternal and/or fetal death.
Mehret Birru Talabi, Sonya Borrero
wiley +1 more source
Paclitaxel plus cetuximab for the treatment of R/M SCCHN after first-line pembrolizumab failure: primary analysis from the PaceAce trial. [PDF]
Fuereder T +11 more
europepmc +1 more source

